Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 USD | 0.00% | -2.64% | +99.32% |
May. 02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 390K | Sales 2025 * | 66.67K | Capitalization | 132M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -57M | EV / Sales 2024 * | 338 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1,979 x |
P/E ratio 2024 * |
-3.02
x | P/E ratio 2025 * |
-2.78
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.33% |
Latest transcript on Cardiff Oncology, Inc.
1 week | -2.64% | ||
Current month | -7.23% | ||
1 month | -12.98% | ||
3 months | -26.98% | ||
6 months | +130.47% | ||
Current year | +99.32% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-11 | 2.95 | 0.00% | 264,267 |
24-06-10 | 2.95 | +0.68% | 567,027 |
24-06-07 | 2.93 | -1.68% | 745,918 |
24-06-06 | 2.98 | 0.00% | 512,324 |
24-06-05 | 2.98 | -1.65% | 518,315 |
Delayed Quote Nasdaq, June 11, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+99.32% | 132M | |
+49.21% | 56.95B | |
+39.98% | 40.26B | |
-6.86% | 39.32B | |
-4.42% | 28.37B | |
+12.00% | 26.45B | |
-18.27% | 19.41B | |
+29.57% | 12.54B | |
+25.41% | 12.21B | |
-0.35% | 12.15B |
- Stock Market
- Equities
- CRDF Stock